Evidence map›Paper›PMID 42368461›Full record

ArticleGynecologic oncology reports2026

Activity of datopotamab deruxtecan in TROP2-expressing low-grade serous ovarian cancer: a preclinical study.

Sarah Ottum, Orazio De Tommasi, Cem Demirkiran, Stefania Bellone, Natalia Buza, Na Niu, Namrata Sethi, Tobias M Hartwich, Alessandro D Santin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sarah OttumDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States.
Orazio De TommasiDepartment of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padua, Padua, Italy.
Cem DemirkiranDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States.
Stefania BelloneDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States.
Natalia BuzaDepartment of Pathology, Yale University School of Medicine, New Haven, CT 06510, United States.
Na NiuDepartment of Pathology, Yale University School of Medicine, New Haven, CT 06510, United States.
Namrata SethiDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States.
Tobias M HartwichDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States.
Alessandro D SantinDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Low-grade serous ovarian carcinoma (LGSOC) is a rare ovarian cancer subtype with limited sensitivity to chemotherapy and modest benefit from endocrine and MEK-directed therapy. New therapeutic targets are needed. We evaluated trophoblast cell-surface antigen 2 (TROP2) expression in LGSOC and the activity of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in an LGSOC patient-derived xenograft (PDX) model. Methods: TROP2 expression was assessed by immunohistochemistry in a retrospective single-center cohort of 29 LGSOC cases treated at Yale University. Antitumor activity of Dato-DXd was evaluated in a TROP2-expressing PDX model derived from a heavily pretreated patient with LGSOC resistant to chemotherapy, aromatase inhibitors, and MEK inhibitors. Results: TROP2 expression was detected in 29 of 29 cases, and 23 tumors showed moderate-to-strong expression. In vivo, Dato-DXd significantly inhibited tumor growth versus vehicle/saline control in a treatment-resistant LGSOC PDX model ( Conclusion: TROP2 is frequently expressed in LGSOC and may represent a therapeutically relevant target. Dato-DXd showed marked antitumor activity in a treatment-resistant LGSOC PDX model. Clinical evaluation in patients with recurrent LGSOC is warranted.

Indexed as

Antibody-drug conjugateDatopotamab deruxtecanLow grade serous ovarian cancerPlatinum-resistant ovarian cancerTrophoblast cell surface antigen 2 (TROP2)

Identifiers

PMID42368461
PMCPMC13293729

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.